 |
|
Further Studies of Antilymphoid Sera in Clinical Renal Allotransplantation
Roy G. Shorter, MD, MRCP, FACP;
George A. Hallenbeck, MD, PhD;
Carl F. Anderson, MD;
William J. Johnson, MD, FACP;
James H. DeWeerd, MD;
Gordon K. Danielson, MD
AMA Arch Surg. 1970;100(2):132-135.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
As a result of reports by others of the properties of heterologous antilymphoid-tissue sera (ALS)1-7 and the results of our own experiences in the laboratory with the use of heterologous antithymus serum as an immunosuppressive agent,8,9 we have continued the trial of horse antihuman thymus serum (HAHTS) in clinical renal allografting. For reasons outlined previously, the serum has been given only as an adjuvant to azathioprine and prednisone, and this limited trial was constructed primarily to assess the problems of its administration. Our decision to use heterologous antithymus tissue serum rather than sera produced by the injection of other lymphoid tissues was also influenced by a report that antithymus sera may provide more effective immunosuppression than other varieties of ALS.10
This report reviews 36 consecutive renal transplant patients, treated with HAHTS, who have been studied for 6 to 18 months following transplantation. The early progress of some
. . . [Full Text PDF of this Article]
Author Affiliations
Rochester, Minn
From the sections of surgery (Drs. Shorter, Hallenbeck, and Danielson), medicine (Drs. Anderson and Johnson), and urology (Dr. DeWeerd), Mayo Clinic and Foundation, Rochester, Minn.
Footnotes
Accepted for publication Oct 18, 1969.
Reprint requests to Mayo Clinic, Rochester, Minn 55901.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
